<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>Collaborative Research: Rational Design of Anticancer Drug Combinations using Dynamic Multidimensional Theory</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>06/15/2016</AwardEffectiveDate>
<AwardExpirationDate>05/31/2020</AwardExpirationDate>
<AwardTotalIntnAmount>240480.00</AwardTotalIntnAmount>
<AwardAmount>240480</AwardAmount>
<AwardInstrument>
<Value>Continuing Grant</Value>
</AwardInstrument>
<Organization>
<Code>03010000</Code>
<Directorate>
<Abbreviation>MPS</Abbreviation>
<LongName>Direct For Mathematical &amp; Physical Scien</LongName>
</Directorate>
<Division>
<Abbreviation>PHY</Abbreviation>
<LongName>Division Of Physics</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Krastan Blagoev</SignBlockName>
<PO_EMAI>kblagoev@nsf.gov</PO_EMAI>
<PO_PHON>7032924666</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This award is part of the NSF effort to promote significant advances in the fundamental understanding of cancer biology made possible through multidisciplinary research that involves experts in theoretical physics, applied mathematics, and computer science.&lt;br/&gt;&lt;br/&gt;Achieving durable control of metastatic solid tumors will require high-order targeted therapeutic combinations, because single-agent therapeutics eventually become thwarted by the development of tumor drug resistance. However, design of combinatorial regimens cannot be done by empirical trial and error in the clinical setting. The goal of the project is to blend a systems biology network-based theoretical framework with an integrated experimental and analytical program in order to address the combinatorial regimen challenge in oncology. Based on areas of exemplary clinical need, investigator expertise, and the availability of patient-derived tumor tissue, the project will focus on BRAF-mutant melanoma and PIK3CA-mutant, estrogen receptor positive (ER+) breast cancer as initial tumor types in which to pilot the approach. In addition the project will offer interdisciplinary training and research experience to postdoctoral and clinical fellows, graduate students, and indirectly to all members of the groups who participate. Professional development of all trainees will be enhanced by yearly meetings of the whole project team which will include tutorials on modeling and experimental methodologies. A symposium on the quantitative science of cancer will be organized at the Dana Farber Cancer Institute during the third year of this project. Team members are also committed to broadening the participation of women and under-represented minorities in STEM fields by pro-active recruitment and mentoring.&lt;br/&gt;&lt;br/&gt;The project will integrate dynamic modeling of signal transduction pathways relevant to cell proliferation and apoptosis, genomic and evolutionary analyses of tumor cells, and systematic cell death and therapeutic resistance studies. The dynamic models will be informed, tested, and iterated using experimental approaches applied to relevant cancer model systems. The experiments leverage emerging technologies such as pooled genome-wide open reading frame screens, dynamic BH3 profiling of cancer cells' closeness to the apoptotic threshold, whole exome sequencing and single cell RNA-seq analysis. The models will recapitulate steady state signaling network activation, acute adaptive effects of treatment (e.g., feedback dysregulation) and the range of drug-resistant states that may emerge following longer-term drug exposure. Tumor cell heterogeneity will be represented by the implementation of different initial configurations or state overrides of network components. Using newly developed systems control methodologies, the models will be used to prioritize drug combinations and dosing/scheduling principles for in vitro and in vivo testing. The final result will be a theoretical and experimentally validated approach that can be generalized across many other cancer types. This project develops a new framework to address cancer as a deregulated complex dynamical system and it will lead to an improved understanding of adaptive and acquired drug resistance mechanisms. The project will make a significant contribution toward a major goal of cancer precision medicine, namely the identification of optimal high-order combinations for individual cancer patients. The project will also establish new connections between evolutionary theory and dynamical systems theory. The theoretical and methodological advances will be applicable or adaptable to other cancers and diseases in general, leading to potentially transformative impacts on human health. &lt;br/&gt;&lt;br/&gt;This proposal is cofunded by the Physics of Living Systems Program in the Physics Division and the Systems and Synthetic Biology Program in the Molecular and Cellular Biosciences Division.</AbstractNarration>
<MinAmdLetterDate>06/09/2016</MinAmdLetterDate>
<MaxAmdLetterDate>06/19/2018</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.049</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1545805</AwardID>
<Investigator>
<FirstName>Raul</FirstName>
<LastName>Rabadan</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME>Dr.</PI_SUFX_NAME>
<PI_FULL_NAME>Raul Rabadan</PI_FULL_NAME>
<EmailAddress>rr2579@cumc.columbia.edu</EmailAddress>
<PI_PHON>2128546851</PI_PHON>
<NSF_ID>000520091</NSF_ID>
<StartDate>06/09/2016</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Columbia University</Name>
<CityName>NEW YORK</CityName>
<ZipCode>100276902</ZipCode>
<PhoneNumber>2128546851</PhoneNumber>
<StreetAddress>2960 Broadway</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<StateCode>NY</StateCode>
<CONGRESSDISTRICT>10</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>NY10</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>049179401</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>049179401</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[Columbia University]]></Name>
<CityName/>
<StateCode>NY</StateCode>
<ZipCode>100277922</ZipCode>
<StreetAddress/>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>13</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>NY13</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1253</Code>
<Text>OFFICE OF MULTIDISCIPLINARY AC</Text>
</ProgramElement>
<ProgramElement>
<Code>7246</Code>
<Text>PHYSICS OF LIVING SYSTEMS</Text>
</ProgramElement>
<Appropriation>
<Code>0116</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0117</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0118</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2016~120000</FUND_OBLG>
<FUND_OBLG>2017~60240</FUND_OBLG>
<FUND_OBLG>2018~60240</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><strong>Project Outcomes Report&nbsp;</strong></p> <p>This project is a collaborative research between several institutions including Dana-Farber/Harvard, Memorial Sloan Kettering, Penn State and Columbia University, the site of the Rabadan&rsquo;s lab. The team has been addressing mechanisms of evolution, diversification, drug resistance and multidrug treatment predictions.</p> <p>Our team at Columbia University has been involved with several projects in this collaborative effort. We would like to highlight the collaboration with&nbsp;&nbsp;Dr. Maurizio Scaltriti from Memorial Sloan Kettering Cancer Center to study the drug resistance in breast cancer. Thanks to the support from this award, there have been multiple high-profile publications from our research.</p> <p>Our research unit focused on using the tumor evolution model we built to study the different patterns of breast cancer under treatment and discover the genomic alteration driving drug resistance. By comparing the clonal evolution patterns of the metastatic tumors and the tumors from neoadjuvant setting, we found striking difference in clonal behavior between them. In neoadjuvant setting all the clonal mutations are shared and there was no acquisition of new mutations after treatment and no apparent (positive or negative) selection at genetic level. While in metastatic cases, there are new mutations acquired after treatment indicating positive selection. There are also mutations lost after treatment indicating potential negative selection. Specifically, in the case of metastatic tumor C-000963 which follows branched evolution pattern, we found ERBB2 mutation gain. Existing study shows that this mutation is activating mutation that likely drive tumorigenesis and drug resistance. In patient C-000513, we found ESR1 mutation in metastatic tumor which drives reduced sensitivity to ER antagonists. In patient C-000964, we found the hypermutation of metastatic tumor is associated with mutation of MSH4 gene. We also found dual PIK3 mutations in this patient. Although most PIK3 mutations are clonal and founding, in this case PIK3 E453 disappeared in treatment, potentially associated to negative selection under therapy. In large scale study, we found dual PIK3 mutations appear common with a preference in temporal order. Functional study shows that dual PIK3 mutations are in cis on the same allele and result in increased PI3K activity, enhanced downstream signaling, increased cell proliferation, and tumor growth. Clinical analysis found that dual PIK3 mutations predict increased sensitivity to PI3Ka inhibitors compared with single-hotspot mutations.</p> <p>In addition, this work has led to the development of genomic based techniques that have been reported in several high impact publications listed below.</p> <p>&nbsp;</p> <p><strong><span style="text-decoration: underline;">Publications</span></strong></p> <p>1. Lee, J.K., Liu, Z., Sa, J.K., Shin, S., Wang, J., Bordyuh, M., Cho, H.J., Elliott, O., Chu, T., Choi, S.W. and Rosenbloom, D.I., 2018. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.&nbsp;<em>Nature genetics</em>,&nbsp;<em>50</em>(10), p.1399.</p> <p>2. Zhao, Junfei, Andrew X. Chen, Robyn D. Gartrell, Andrew M. Silverman, Luis Aparicio, Tim Chu, Darius Bordbar et al. "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma." Nature medicine 25, no. 3 (2019): 462-469.</p> <p>3. Liu, Zhaoqi, Akihide Yoshimi, Jiguang Wang, Hana Cho, Stanley Chun-Wei Lee, Michelle Ki, Lillian Bitner et al. "Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization." Cancer Discovery (2020).</p> <p>4. Vasan, Neil, Pedram Razavi, Jared L. Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig et al. "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K&alpha; inhibitors." Science 366, no. 6466 (2019): 714-723.</p> <p>&nbsp;</p> <p>&nbsp;</p><br> <p>            Last Modified: 06/02/2020<br>      Modified by: Raul&nbsp;Rabadan</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ Project Outcomes Report   This project is a collaborative research between several institutions including Dana-Farber/Harvard, Memorial Sloan Kettering, Penn State and Columbia University, the site of the Rabadanâ€™s lab. The team has been addressing mechanisms of evolution, diversification, drug resistance and multidrug treatment predictions.  Our team at Columbia University has been involved with several projects in this collaborative effort. We would like to highlight the collaboration with  Dr. Maurizio Scaltriti from Memorial Sloan Kettering Cancer Center to study the drug resistance in breast cancer. Thanks to the support from this award, there have been multiple high-profile publications from our research.  Our research unit focused on using the tumor evolution model we built to study the different patterns of breast cancer under treatment and discover the genomic alteration driving drug resistance. By comparing the clonal evolution patterns of the metastatic tumors and the tumors from neoadjuvant setting, we found striking difference in clonal behavior between them. In neoadjuvant setting all the clonal mutations are shared and there was no acquisition of new mutations after treatment and no apparent (positive or negative) selection at genetic level. While in metastatic cases, there are new mutations acquired after treatment indicating positive selection. There are also mutations lost after treatment indicating potential negative selection. Specifically, in the case of metastatic tumor C-000963 which follows branched evolution pattern, we found ERBB2 mutation gain. Existing study shows that this mutation is activating mutation that likely drive tumorigenesis and drug resistance. In patient C-000513, we found ESR1 mutation in metastatic tumor which drives reduced sensitivity to ER antagonists. In patient C-000964, we found the hypermutation of metastatic tumor is associated with mutation of MSH4 gene. We also found dual PIK3 mutations in this patient. Although most PIK3 mutations are clonal and founding, in this case PIK3 E453 disappeared in treatment, potentially associated to negative selection under therapy. In large scale study, we found dual PIK3 mutations appear common with a preference in temporal order. Functional study shows that dual PIK3 mutations are in cis on the same allele and result in increased PI3K activity, enhanced downstream signaling, increased cell proliferation, and tumor growth. Clinical analysis found that dual PIK3 mutations predict increased sensitivity to PI3Ka inhibitors compared with single-hotspot mutations.  In addition, this work has led to the development of genomic based techniques that have been reported in several high impact publications listed below.     Publications  1. Lee, J.K., Liu, Z., Sa, J.K., Shin, S., Wang, J., Bordyuh, M., Cho, H.J., Elliott, O., Chu, T., Choi, S.W. and Rosenbloom, D.I., 2018. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature genetics, 50(10), p.1399.  2. Zhao, Junfei, Andrew X. Chen, Robyn D. Gartrell, Andrew M. Silverman, Luis Aparicio, Tim Chu, Darius Bordbar et al. "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma." Nature medicine 25, no. 3 (2019): 462-469.  3. Liu, Zhaoqi, Akihide Yoshimi, Jiguang Wang, Hana Cho, Stanley Chun-Wei Lee, Michelle Ki, Lillian Bitner et al. "Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization." Cancer Discovery (2020).  4. Vasan, Neil, Pedram Razavi, Jared L. Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig et al. "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K&alpha; inhibitors." Science 366, no. 6466 (2019): 714-723.             Last Modified: 06/02/2020       Submitted by: Raul Rabadan]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
